Morepen Laboratories Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/5apojet30j0g4gwa30wd5g9n.pdf

Key Takeaways


Revenue Growth & Segment Mix

Sushil Suri: "for the first time almost after 25-30 years, the company has started paying tax and we are a tax paying company, we have paid Rs. 25 crores tax this year."

Margin Pressure & Cash Flow

Sushil Suri: "Montelukast is sold in the domestic market as you would appreciate domestic markets are not that profitable, so we have to have some compromise in the margins which is obvious in our results"

Medical Devices: Growth Deceleration & Inventory Risk


Key Products & Market Share

ProductFY22 PerformanceCommentary
Montelukast▲ 65% growthDriven by domestic market; export market share rose from 30% to 49.2%. Domestic sales are less profitable, creating margin pressure.
Loratadine▬ 1% growthGlobal market slowed due to mask usage and vaccination reducing flu/allergies; decline in first two quarters was recovered in the next two. Export market share out of India rose to 68% from 60%.
Atorvastatin▲ 18% growthSteady contributor.
New molecules▲ 689% growthOn a very small base; some products under patent with small R&D shipments ongoing.
FexofenadineNew launchUS exports commenced in Q4 after November US FDA approval; 70% of Fexofenadine is export. Approximate contribution ~₹14-15 crores in Q4.

Balance Sheet & Capital Structure

Sushil Suri: "We are proud to say we are a zero-debt company, we do not have any borrowings. Normally, what happens is in case our has grown by 30%, so there is an increase in working capital by 30%, if not 30, maybe 25%. So, our growth is a big constraint because we are depending only on the profits and that is why we do not have even less CAPEX because whatever we are investing that is going to the working capital."

Regulatory & Competitive Position


Guidance & Commitments

CommitmentSpecificsTimeline
Margin recoveryMaintain last year's average margins, not the Q4 marginsFY23
Cash flow releaseInventory will ease out; both debtors and inventory will release cash flowQ1 FY23
Fexofenadine US ramp-upSupplies to US have started and will contribute to continued US growthOngoing from Q4 FY22
Sitagliptin launchFree to sell after patent expiry; technology, processes, and tie-ups readyJuly 2022
Medical devices export restartInternational certification audits may resume; facilities ready for inspection2-3 quarters before export business restarts
Warrant conversionRemaining warrants will be convertedBefore September 2022
Dividend decisionBoard to take call after preference share conversion clarity; policy at AGMForthcoming AGM
Near-term stabilizationNumbers to stabilize and return to desired growth trajectoryOne or two quarters more

Key Metrics

MetricQ4 FY22
Revenue₹372 cr, +28% YoY
Full-year revenue₹1,557 cr, +30% YoY
Full-year PBT+29% YoY
Full-year PAT+5% YoY; ₹25 cr tax incidence on ₹126 cr profit
Full-year EBITDA₹130 cr, +13% YoY
Cash from operationsNegative ₹58 cr (full year); ₹168 cr invested in receivables and inventory
Operating margin~5% (Q4), down from ~8% in Q3 and 10–11% earlier; full-year 7.66% vs 8.36%
Net marginDown ~150 bps (full year)
API segment revenue₹235 cr, +37% YoY; full-year +26% to ₹863 cr (per an analyst's math)
Medical devices segment revenue₹419 cr (full year), +46% YoY; Q4 growth ~10%
Formulations segment revenue₹169 cr (full year), +28% YoY; Q4 +34%
OTC segment revenue₹106 cr (full year), +23% YoY
Dr. Morepen brand topline₹685 cr (full year), +36%
Export revenue₹557 cr (full year), +17% YoY; Q4 +39%
Domestic revenue+38% YoY (full year); Q4 +20%
API export share64%, down from 67%
Montelukast revenue growth+65% YoY (full year)
Loratadine export market share68% (out of India), up from 60%
Montelukast export market share49.2%, up from 30%
Glucometers revenue₹279 cr (full year), +59% YoY; 0.22 cr meters installed this year
BP monitors revenue₹84 cr (full year); 0.19 cr meters sold
Debtors turnover1.70 months, up from 1.63 months
Inventory turnover4.65 months, down from ~5 months
R&D spend+34% YoY (full year)